
Eli Lilly and Insilico Medicine have struck a new deal on AI-driven drug discovery, the companies announced on Sunday.
Under the agreement, worth up to $2.75 billion (€2.39 billion), the American firm Eli Lilly will use Insilico’s artificial intelligence (AI) platform to accelerate the discovery and development of novel therapeutics across multiple therapeutic areas.